Status:
COMPLETED
Semaglutide Use in Acute Pulmonary Embolism
Lead Sponsor:
Imperial College London
Conditions:
Pulmonary Embolism
Eligibility:
All Genders
18-80 years
Brief Summary
Evaluation of circulating endothelial inflammatory biomarkers in response to GLP-1 agonist Semaglutide in acute pulmonary embolism
Detailed Description
Study Rationale and risk/benefit analysis This GLP-1 intervention study in patients with acute PE represents an original hypothesis in a population with unmet clinical need. The results of this study...
Eligibility Criteria
Inclusion
- Acute pulmonary embolism
Exclusion
- Concurrent use of GLP-1 agonist
Key Trial Info
Start Date :
January 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 5 2023
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT06118203
Start Date
January 2 2022
End Date
March 5 2023
Last Update
November 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Colm McCabe
London, United Kingdom, SW3 6NP